ATE380554T1 - Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie - Google Patents

Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie

Info

Publication number
ATE380554T1
ATE380554T1 AT04768829T AT04768829T ATE380554T1 AT E380554 T1 ATE380554 T1 AT E380554T1 AT 04768829 T AT04768829 T AT 04768829T AT 04768829 T AT04768829 T AT 04768829T AT E380554 T1 ATE380554 T1 AT E380554T1
Authority
AT
Austria
Prior art keywords
hypothermia
xenon
asphyxia
treat newborn
treat
Prior art date
Application number
AT04768829T
Other languages
German (de)
English (en)
Inventor
Nicholas Peter Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34436835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE380554(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0323861A external-priority patent/GB0323861D0/en
Priority claimed from GB0418539A external-priority patent/GB0418539D0/en
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of ATE380554T1 publication Critical patent/ATE380554T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT04768829T 2003-10-10 2004-10-11 Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie ATE380554T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0323861A GB0323861D0 (en) 2003-10-10 2003-10-10 Use
GB0418539A GB0418539D0 (en) 2004-08-19 2004-08-19 Use

Publications (1)

Publication Number Publication Date
ATE380554T1 true ATE380554T1 (de) 2007-12-15

Family

ID=34436835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768829T ATE380554T1 (de) 2003-10-10 2004-10-11 Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie

Country Status (13)

Country Link
US (1) US7390508B2 (enExample)
EP (1) EP1670489B1 (enExample)
JP (1) JP4880466B2 (enExample)
AT (1) ATE380554T1 (enExample)
AU (1) AU2004280118B2 (enExample)
BR (1) BRPI0415232A (enExample)
CA (1) CA2538104C (enExample)
DE (1) DE602004010691T2 (enExample)
DK (1) DK1670489T3 (enExample)
ES (1) ES2298815T3 (enExample)
MX (1) MXPA06003471A (enExample)
PT (1) PT1670489E (enExample)
WO (1) WO2005034966A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2538104C (en) * 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
AU2014277860A1 (en) * 2008-01-22 2015-01-22 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
US20110159078A1 (en) * 2008-01-22 2011-06-30 Vapogenix, Inc Volatile Anesthetic Compositions and Methods of Use
EP3195896A1 (en) * 2009-05-05 2017-07-26 Board of Regents, The University of Texas System Novel formulations of volatile anesthetics and methods of use for reducing inflammation
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
CN110354067A (zh) 2013-03-15 2019-10-22 德克萨斯州大学系统董事会 富含稀有气体的液体及其制备和使用方法
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
JP6622822B2 (ja) 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6653354B2 (en) * 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
WO2001078580A2 (en) * 2000-03-31 2001-10-25 Innercool Therapies, Inc. A method combining inducing hypothermia and administering a therapeutic agent
CA2538104C (en) * 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia

Also Published As

Publication number Publication date
DE602004010691T2 (de) 2008-12-04
AU2004280118A1 (en) 2005-04-21
EP1670489A1 (en) 2006-06-21
EP1670489B1 (en) 2007-12-12
BRPI0415232A (pt) 2006-12-12
CA2538104C (en) 2013-12-10
US7390508B2 (en) 2008-06-24
DK1670489T3 (da) 2008-01-07
JP4880466B2 (ja) 2012-02-22
AU2004280118B2 (en) 2009-01-15
WO2005034966A1 (en) 2005-04-21
US20070104796A1 (en) 2007-05-10
DE602004010691D1 (de) 2008-01-24
MXPA06003471A (es) 2006-06-14
CA2538104A1 (en) 2005-04-21
PT1670489E (pt) 2008-02-28
ES2298815T3 (es) 2008-05-16
JP2007508284A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
MX375532B (es) Usos de inhibidores de dpp iv.
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
DE602007004615D1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
ATE247507T1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
ATE473735T1 (de) Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
DE602005024571D1 (de) Opioide zur behandlung von ruhelosigkeit in den unteren gliedmassen
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
ATE304854T1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE602005013542D1 (de) Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
DE60326179D1 (de) Pflanzliche zubereitung zur behandlung von magengeschwüren
ATE476185T1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1670489

Country of ref document: EP